Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV-RNA VIRAL LOAD REDUCTION OF .5 LOG IS PREDICTIVE OF CLINICAL BENEFIT -- FDA ADVISORY CMTE.; FUTURE OF HIV TREATMENT IS INDIVIDUALIZING THERAPY -- FDA's FEIGAL

Executive Summary

A .5 log reduction in HIV-RNA viral load is an acceptable indicator of virologic response in clinical trials of experimental HIV drugs, FDA's Antiviral Drugs Advisory Committee agreed at its July 14-15 meeting.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS030538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel